1 | 5 ASA, enemas, suppositories, corticosteroids | - | - | - | - | [1] 97 97 |
2 | ACEI/ARB and corticosteroids | - | - | - | - | [1] 66 66 |
3 | Azithromycin + N-acetylcystein + inhaled corticosteroid | [1] Azithromycin Azithromycin | [3] D02134
D02134
,
D06390
,
D07486
| - | - | [1] 228 228 |
4 | Behavioral: Duchenne Muscular Dystrophy group without Corticosteroids therapy | - | - | - | - | [1] 113 113 |
5 | Chronic Corticosteroid Therapy | - | - | - | - | [1] 113 113 |
6 | Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids | [1] Rituximab Rituximab | [1] D02994
D02994
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 85 85 |
7 | Corticosteroid | - | - | - | - | [10] 13 13, 42, 43, 44, 45, 66, 84, 96, 97, 222 |
8 | Corticosteroid (CS) | - | - | - | - | [1] 41 41 |
9 | Corticosteroid (prednisolone) | [1] Prednisolone Prednisolone | [8] D00472
D00472
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 85 85 |
10 | Corticosteroid and azathioprine | [1] Azathioprine Azathioprine | [2] D00238
D00238
,
D03033
| - | - | [4] 42 42, 43, 44, 45 |
11 | Corticosteroid and non-biological agents. | - | - | - | - | [1] 46 46 |
12 | Corticosteroid or NSAID | - | - | - | - | [1] 46 46 |
13 | Corticosteroid treatment (Methylprednisolone or prednisolone) | [2] Methylprednisolone Methylprednisolone, Prednisolone | [14] D00407
D00407
,
D00472
,
D00751
,
D00979
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
,
D05000
,
D05001
,
D05002
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 64 64 |
14 | Corticosteroids | - | - | - | - | [10] 41 41, 46, 49, 64, 97, 107, 164, 220, 296, 300 |
15 | Corticosteroids & tanCART19/20 | - | - | - | - | [1] 13 13 |
16 | Corticosteroids (Aprednislon) | - | - | - | - | [1] 63 63 |
17 | Corticosteroids (prednisone or prednisolone) | [2] Prednisolone Prednisolone, Prednisone | [9] D00472
D00472
,
D00473
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 49 49 |
18 | Corticosteroids for Systemic Use | - | - | - | - | [1] 41 41 |
19 | Corticosteroids only | - | - | - | - | [1] 97 97 |
20 | Corticosteroids'therapy | - | - | - | - | [1] 35 35 |
21 | CS (corticosteroids) Only | - | - | - | - | [1] 97 97 |
22 | Cumulative corticosteroid exposure | - | - | - | - | [1] 49 49 |
23 | H02 - Corticosteroidi Sistemici | - | - | - | - | [1] 299 299 |
24 | Intra-articular corticosteroid injection | - | - | - | - | [1] 46 46 |
25 | IV Corticosteroid | - | - | - | - | [1] 97 97 |
26 | Oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone | [2] Mesalazine Mesalazine, Methylprednisolone | [7] D00377
D00377
,
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 97 97 |
27 | Oral corticosteroids | - | - | - | - | [4] 13 13, 46, 97, 171 |
28 | Oral corticosteroids (OCS) | - | - | - | - | [1] 162 162 |
29 | Treatment with topical superpotent corticosteroid therapy | - | - | - | - | [1] 162 162 |
30 | Valproid acid plus corticosteroids | - | - | - | - | [1] 26 26 |